Physician profile
Anu Dham
NPI 1255375531
$8,614.98
in general payments reported to CMS, 2019-2025
58 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,283 · 2020: $1,180 · 2021: $1,205 · 2022: $988 · 2023: $263 · 2024: $501 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Education: $74.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.48 |
| Education | $74.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $2,150.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $720.43 | 2019-2025 | |
| Amgen INC. | $513.17 | 2019-2025 | Vectibix |
| Merck Sharp & Dohme LLC | $414.56 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $402.50 | 2019-2023 | |
| Janssen Biotech, INC. | $395.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $371.87 | 2019-2024 | Enhertu |
| Eisai INC. | $303.88 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $219.46 | 2024 | Myrisk |
| Pfizer INC. | $214.29 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $212.41 | 2019-2024 | Ultomiris |
| Incyte Corporation | $191.99 | 2019-2021 | |
| Genzyme Corporation | $161.08 | 2019-2022 | |
| Celgene Corporation | $156.45 | 2019-2025 | Reblozyl |
| Lilly USA, LLC | $155.85 | 2019-2023 | Verzenio |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Dham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.